Pacific Biosciences of California, Inc. (PACB) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Stay updated on Pacific Biosciences of California, Inc. (PACB) stock with short-term forecast for year 2025 and long-term price prediction for 2025 - 2050. Access historical performance, see analyst ratings, and follow the latest Pacific Biosciences of California, Inc. news and developments.
1 Month Prediction
$1.00 [-18.03%]
3 Month Prediction
$1.00 [-18.03%]
6 Month Prediction
$1.00 [-18.03%]
1 Year Prediction
$1.00 [-18.03%]
3 Year Prediction
$1.00 [-18.03%]
5 Year Prediction
$1.00 [-18.03%]
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PacBio) is a biotechnology company that develops and manufactures advanced sequencing solutions for genetic analysis. Founded in 2000 as Nanofluidics, Inc., the company rebranded to its current name in 2005, and is headquartered in Menlo Park, California. Currently, PacBio has approximately 796 employees.
PacBio's products include sequencing systems such as the Revio and Sequel platforms, which utilize Single Molecule Real-Time (SMRT) sequencing technology that enable real-time analysis of single-molecule biochemical reactions, providing high accuracy and long-read capabilities essential for genomic studies.
Also, PacBio offers a range of consumables designed to support specific sequencing workflows. These include SMRT Cells, which contain zero-mode waveguides (ZMWs) for single-molecule detection, and various reagent kits for DNA preparation, binding, and sequencing processes.
PacBio markets its products through a direct sales force and distribution partners across Asia, Australia, Europe, the Middle East, Africa, and Latin America.
Pacific Biosciences of California, Inc. (PACB) Historical Performance
IPO Date
Pacific Biosciences of California, Inc. (NASDAQ:PACB) went public on 27 October, 2010.
Change
Since inception, PACB has decreased by 92.74%. In the last 5 years, PACB has fallen from $3.31 to $1.22, a massive -63.14% decrease since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $34.97 and a low of $1.22.
52 Week Range
$1.16
$4.1
The current price $1.22 is near the 52-week low, which means that the stock is underbought.
PACB Stock Price History
Based on PACB stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the PACB stock has fallen from $3.06 - $25.94 to $1.22 - $1.54, which is down -75.47%. Currently, the stock follows downward trend.
Here, we have calculated stock range of PACB, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $3.06 - $25.94 | $8.04 | 40.86 | 1 Year Change |
| 2021 | $20.46 - $34.97 | $28.94 | 407.03 | 2 Year Change |
| 2022 | $4.37 - $11.92 | $7.67 | 34.38 | 3 Year Change |
| 2023 | $6.18 - $13.3 | $10.45 | 83.08 | 4 Year Change |
| 2024 | $1.37 - $6.51 | $2.64 | -53.75 | 5 Year Change |
| 2025 | $1.22 - $1.54 | $1.4 | -75.47 | 6 Year Change |
PACB Price Performance
6-Month Performance
PACB stock dropped by 43.78% in the last six months.
1-Year Performance
The stock has trended downwards by 26.06% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 80.76%.
5-Year Performance
In the last 5 years, the stock has gone down by 63.14%.
According to Pacific Biosciences of California, Inc.'s historical data, below graph gives us the exact picture of how the PACB stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 2 years and a decline in 3 years.
2020
404.67% ↑
2021
21.13% ↓
2022
60.02% ↓
2023
19.93% ↑
2024
81.35% ↓
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Pacific Biosciences of California, Inc. (PACB) Financials & Stock Analysis
Total Revenue
Quarterly Revenue: $39.97 M (Q3)
Revenue for Q3 ending 30th September, 2024 increased 10.98% compared to Q2 ending 30th June, 2024.
Annual Revenue: $173.15 M (1Y)
Revenue for trailing 12 months decreased 13.65% year over year from 31st December, 2023.
If compared to the last 5 years, the revenue has gone up from $78.89 million to $173.15 million, a 119.47% change.
Market Capitalization
Pacific Biosciences of California, Inc. has a market capitalization of $359.06M, which places PACB in the small-cap category.
Fundamental Analysis
EPS: $-0.22 (Q3), $-1.21 (1Y)
EPS decreased 65.62% since last quarter, and decreased 13.57% since last year.
Net Income: $-60.73 M (Q3), $-306.74 M (1Y)
Net Income decreased 64.96% since last quarter, and decreased 2.39% since last year.
Free Cash Flow: $-44.68 M (Q3), $-268.02 M (1Y)
Free Cash Flow decreased 19.85% since last quarter, and decreased 4.33% since last year.
Net Profit Margin: -151.94% (Q3), -177.15% (1Y)
Net Profit Margin decreased 68.43% since last quarter, and increased 13.04% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for PACB stock. These indicators help you understand Pacific Biosciences of California, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for PACB stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $1.47 |
| SMA50 | $1.60 |
| SMA200 | $1.74 |
| RSI | 25.30 |
| Beta | 1.86 |
SMA20 > Current Price
This signals PACB stock is in short-term bearish momentum.
SMA50 > Current Price
This signals PACB stock is in mid-term bearish momentum.
SMA200 > Current Price
This signals PACB stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for PACB stock is Bearish. Out of all indicators, 3 indicates bullish signals, 5 signals bearish trends and 1 gives neutral trends. The PACB stock forecast was last updated on 15 March, 2025.
Pacific Biosciences of California, Inc. (PACB) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to fall to $1.00 by the end of 2025, and can reach around $1.02 to $1.04 in 2026. And, the long-term forecast suggests that the stock may further drop to $0.50 - $1.07 in 2028, and $1.21 - $1.00 by 2031. So, the PACB stock shows a strong downward trend in the next several years.
Short-term PACB Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-04 | $1.00 | -18.03% |
| 2025-05 | $1.00 | -18.03% |
| 2025-06 | $1.00 | -18.03% |
| 2025-07 | $1.00 | -18.03% |
| 2025-08 | $1.00 | -18.03% |
| 2025-09 | $1.00 | -18.03% |
| 2025-10 | $1.00 | -18.03% |
| 2025-11 | $1.00 | -18.03% |
| 2025-12 | $1.00 | -18.03% |
In 2025, the PACB stock price is expected to fluctuate between $1.0 and $1.0. According to the monthly forecast, the stock could drop to $1.00 by December 2024. If compared to the PACB's current price, the stock could lose -18.03% by the end of this year.
Long-term PACB Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $1.02 | $0.88 | $1.04 | -14.75% |
| 2027 | $0.76 | $1.25 | $0.91 | -25.41% |
| 2028 | $0.50 | $0.46 | $1.07 | -12.3% |
| 2029 | $0.91 | $0.82 | $0.70 | -42.62% |
| 2030 | $1.10 | $0.50 | $0.93 | -23.77% |
| 2031 | $1.21 | $0.33 | $1.00 | -18.03% |
| 2032 | $0.56 | $0.93 | $1.11 | -9.02% |
| 2033 | $0.98 | $1.00 | $1.13 | -7.38% |
| 2034 | $0.87 | $1.45 | $0.35 | -71.31% |
| 2035 | $0.97 | $1.31 | $1.33 | 9.02% |
| 2036 | $1.18 | $0.91 | $0.53 | -56.56% |
| 2037 | $1.44 | $0.67 | $1.05 | -13.93% |
| 2038 | $0.88 | $0.92 | $1.11 | -9.02% |
| 2039 | $1.31 | $1.27 | $1.37 | 12.3% |
| 2040 | $1.06 | $0.79 | $1.23 | 0.82% |
| 2041 | $0.85 | $1.27 | $0.82 | -32.79% |
| 2042 | $1.24 | $0.68 | $1.18 | -3.28% |
| 2043 | $1.05 | $1.14 | $1.11 | -9.02% |
| 2044 | $1.14 | $1.23 | $1.07 | -12.3% |
| 2045 | $1.50 | $1.03 | $1.14 | -6.56% |
| 2046 | $1.31 | $1.08 | $0.89 | -27.05% |
| 2047 | $1.08 | $0.93 | $1.72 | 40.98% |
| 2048 | $1.09 | $1.19 | $1.09 | -10.66% |
| 2049 | $0.89 | $1.15 | $1.01 | -17.21% |
| 2050 | $1.29 | $1.37 | $1.20 | -1.64% |
| 2051 | $0.34 | $1.25 | $1.20 | -1.64% |
Pacific Biosciences of California, Inc. (PACB) Stock Price Prediction & Forecast 2025
At the start of 2025, the PACB stock was at $1.54. Today, it is trading at $1.22, which is -20.78% decrease from price at the beginning of the year. By the end of this year, you can expect the stock to fall to $1.00 by December 2025 with a -18.03% change.
Pacific Biosciences of California, Inc. (PACB) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant depreciation in the PACB stock. During this period, the PACB's price is forecasted to shift from $1.02 to $0.93, which is -8.82% loss.
In 2026, the stock would possibly open at $1.02, descends to $0.88 by mid-year, and wraps up at $1.04, reflecting a decrease from today's price. Further moving to 2030, the stock can kick off the year at $1.10, drop to $0.50 by mid-year, and finish at $0.93, which is -23.39% change from current price.
Pacific Biosciences of California, Inc. (PACB) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $1.21 to $1.23, which is up -18.35%
In 2031, we can expect PACB to fluctuate between $1.00 and $1.21, a shift indicating a -18.35% loss by year-end compared to current price. And Until 2040, PACB can likely vary from $1.06 to $1.23. By the end of 2040, the stock could record a 0.86% rise from today's stock price.
Pacific Biosciences of California, Inc. (PACB) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the PACB stock can see an an upturn from $0.85 to $1.20 in this period. In 2041, the stock can experience a high of $1.27 by mid-year, closing the year at $0.82. This results in a 4.43% increase from today.
Moving towards the end of 2050, PACB is projected to open the year at $1.29. The stock may peak to $1.37 during mid-year and finish the year at $1.20. Compared to the stock's current price, this translates to an overall loss of -1.56% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
PACB Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| TNON | Tenon Medical, Inc. | - | $3.75 | 179.85% ▲ | -73.33 ▼ |
| MASS | 908 Devices Inc. | - | $3.88 | 73.21% ▲ | $53.69 ▲ |
| RSLS | ReShape Lifesciences Inc. | - | $1.36 | -63.93% ▼ | $463.57 ▲ |
| DXCM | DexCom, Inc. | - | $61.63 | -9.75% ▼ | $98.63 ▲ |
| TIVC | Tivic Health Systems, Inc. | - | $4.83 | 88.67% ▲ | -79.3 ▼ |
Last updated Mar 15 at 2 PM
PACB : Buy, Sell Or Hold?
Analyst Ratings
Based on 14 analysts, 1 rated as a strong buy, 5 recommended a buy, 8 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.So, according to analyst ratings, the recommendation for PACB stock is Hold.Expert Analysis
According to PACB short-term and long-term forecast, Pacific Biosciences of California, Inc. shares are projected to go down by 1.64%, and reach a value of $1.20 per share by 2050.
As per technical analysis, indicators show a Bearish sentiment, while Fear & Greed Index stands at 28.571428571428573, which signals Fear. Also, PACB has recorded 10/30 green days, which reflects a 45.45454545454545% positivity rate with a price volatility of 0.08%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that PACB stock is undervalued. So, Based on PACB prediction and analysis, it may be the best time to sell PACB stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "PACB” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.